Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
KARD
STRONG SELLKardigan, Inc. · Healthcare · United States · $1.9B
8
StockRankGet insider-trade alerts
Q
32
V
25
M
24
P/E (TTM)
—
ROE
—
D/E
0.0x
Dividend %
—
Loading 1Y...
PRICE (1Y)-3.5%
Close
$21.23
RSI (14)
39.3
SCORE BREAKDOWN
Quality
32
ROIC
-57.1%13.5
ROE
—N/A
GP/Assets
—N/A
Op. Margin
0.0%41.3
FCF/Assets
-40.3%7.1
Piotroski
239.0
Int. Cover
—N/A
D/E Ratio
0.05x71.7
Current Ratio
9.41x85.3
Value
25
P/E (TTM)
—N/A
EV/EBITDA
-7.2x25.0
P/FCF
—N/A
P/B
-1.1x25.0
P/S
—N/A
Div Yield
—N/A
Momentum
24
52W High %
—N/A
RS 6M
—N/A
SMA 50/200
—N/A
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
-17%15.5
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$1.9B
P/E (Forward)
-6.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of KARD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| KARD | Kardigan, Inc.(you) | $1.9B | 8 | STRONG SELL |
| GENB | Generate Biomedicines, Inc. | $1.7B | 8 | STRONG SELL |
| OCUL | Ocular Therapeutix, Inc. | $1.9B | 9 | STRONG SELL |
| KLRA | Kailera Therapeutics, Inc. | $2.3B | 9 | STRONG SELL |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.6B | 5 | STRONG SELL |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 11 | STRONG SELL |
| VRDN | Viridian Therapeutics, Inc. | $2.1B | 3 | STRONG SELL |
| VERA | Vera Therapeutics, Inc. | $2.5B | 9 | STRONG SELL |
| MPLT | MapLight Therapeutics, Inc. | $1.7B | 14 | STRONG SELL |
| SNDX | Syndax Pharmaceuticals, Inc. | $1.8B | 16 | STRONG SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%